START Partners with Trialing to Expand Access to Oncology Clinical Trials Across Europe
核心洞察
The START Center for Cancer Research (搜索), the world's largest community-based network of early-phase oncology trial sites, has formed a strategic partnership with Trialing (搜索) to enhance physician awareness and streamline patient referrals across Europe.
The collaboration will distribute curated information on active oncology clinical trials and provide real-time study updates to medical oncologists through Trialing (搜索)'s physician network platform.
START has conducted more than 1,000 early-phase clinical trials across its 15 clinical trial sites, including studies for 50 therapies that received FDA or EMA approval.
The START Center for Cancer Research (搜索) has announced a strategic partnership with Trialing (搜索) to expand access to oncology clinical trials across Europe, addressing what executives describe as one of the greatest barriers in cancer research. The collaboration between the world's largest community-based network of early-phase oncology trial sites and the physician-driven clinical trial platform aims to streamline referrals and improve patient access to innovative cancer therapies.
Partnership Framework
Through this exclusive collaboration, START will work with Trialing (搜索) to distribute curated information on active oncology clinical trials, share real-time study updates, and notify medical oncologists when enrollment slots become available through Trialing's physician network. The partnership is designed to reduce friction in the referral process while increasing physician awareness of available trial opportunities.
"Access remains one of the greatest barriers in oncology clinical research," said Nick Slack, MBE, Chairman and CEO of START. "Partnering with Trialing (搜索) allows us to engage physicians on a platform they already know and trust, provide clear and timely visibility into our hundreds of active trials, and make it easier to connect patients with START's clinical trial sites across Europe."
Technology-Driven Approach
Trialing (搜索) leverages innovative technology, accurate data, and an agile, physician-focused approach supported by its internal medical team to revolutionize clinical trial access. The platform connects physicians, patients, and the pharmaceutical industry through structured clinical decision pathways, enabling faster identification of appropriate studies and reducing barriers to trial participation.
The platform will enable START to provide dynamic study updates, ensuring physicians have current information on eligibility criteria and enrollment status. This real-time information sharing represents a key factor in reducing delays and missed referral opportunities, according to company executives.
Clinical Impact and Network Expansion
START's European network of clinical trial sites continues to grow, maintaining a strong focus on accelerating early-phase trials while preserving deep relationships with referring physicians and community oncologists. The organization has conducted more than 1,000 early-phase clinical trials across its 15 clinical trial sites, including studies for 50 therapies that were subsequently approved by the FDA or EMA.
"Clinical trial awareness and referral efficiency are critical to advancing cancer care," said Dr. Emiliano Calvo, President of START Europe. "By partnering with Trialing (搜索), we can more effectively share study availability with medical oncologists and ensure patients are referred at the right time, when enrollment opportunities are open."
Platform Integration
Trialing (搜索) combines curated clinical trial data, clinical expertise from its medical team, physician-centered discovery tools, and emerging AI-supported screening capabilities to help oncologists rapidly identify appropriate studies and streamline referrals to recruiting research sites. The platform supports a growing network of oncologists and research centers across Europe and the United States.
"We're proud to partner with START, an organization that shares our commitment to improving access to clinical trials through smarter, more connected solutions," said Max Hardy-Werbin, CEO of Trialing (搜索). "Together, we're empowering physicians with the information they need to quickly identify appropriate trials and helping patients reach innovative treatment options without unnecessary friction."
The partnership reflects a shared vision to modernize clinical trial access, strengthen physician engagement, and accelerate oncology research across Europe, with both organizations committed to bringing innovative research closer to patients through improved transparency and communication pathways.